Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons with HIV Receiving Tenofovir Alafenamide and Emtricitabine-based Antiretroviral Therapy (QUANTI-TAF).

Ryan P CoyleMary MorrowSarah C MannVincent MainellaSamuel L EllisStefanie SchwabCorwin CoppingerNicholas BarkerLucas EllisonJia-Hua ZhengSubhi Al ZuabiPamela E AlpertTony C CarnesD Eric BuffkinPeter Ray ChaiLane R BushmanJennifer J KiserSamantha MaWhinneyKristina M BrooksPeter L AndersonJose R Castillo-Mancilla

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)

We propose PK-based TFV-DP (≥1800 fmol/punches)/FTC-TP (≥2.5 pmol/punches) benchmarks in DBS for PWH receiving unboosted TAF/FTC-based ART with ≥85% adherence. In the setting of high adherence, low-level viremia was common.

Keyphrases

antiretroviral therapy
hiv infected
human immunodeficiency virus
hiv positive
hiv infected patients
hiv aids
glycemic control
type diabetes
south africa
weight loss